In addition, KRAS mutation has been proposed as a mechanism of primary resistance to EGFR TKI [18], and many studies demonstrated poor clinical outcomes to EGFR TKIs in patients with NSCLC harboring KRAS mutation [7], [9], [19], [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.